https://www.live-feeds.com/feed/another-heart-drug-fails-shocking-cardiologistsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/another-heart-drug-fails-shocking-cardiologistshttps://www.live-feeds.com/feed/another-heart-drug-fails-shocking-cardiologists#u61605Tue, 08 Sep 2026 16:07:12 +0000Novartis announced that pelacarsen failed to achieve its primary outcome in the Lp(a)HORIZON trial. While the drug successfully lowered lipoprotein(a), it did not reduce cardiovascular events in patients with established disease and elevated Lp(a). This represents the first cardiovascular outcomes trial for an agent designed to lower Lp(a), a protein particle associated with higher heart risk in roughly one in five people. There are currently no approved therapies to lower Lp(a), which is primarily determined by genetics.Why it mattersCardiologists viewed this drug as a potential breakthrough https://www.live-feeds.com/feed/another-heart-drug-fails-shocking-cardiologistshttps://www.live-feeds.com/feed/another-heart-drug-fails-shocking-cardiologists#u58950Sun, 06 Sep 2026 11:35:09 +0000An experimental cardiovascular drug developed by Novartis and Ionis called pelacarsen failed its Phase III Lp(a)HORIZON trial. The late-stage study targeted patients with established cardiovascular disease and elevated Lp(a). Although the treatment successfully lowered levels of the Lp(a) protein particle, it failed to protect heart health or meet its primary endpoint. This unexpected outcome has surprised cardiologists and raised broader questions about the future of this emerging class of heart medications.Why it mattersThe unsuccessful trial represents a major setback for researchers pursui https://www.live-feeds.com/feed/another-heart-drug-fails-shocking-cardiologistshttps://www.live-feeds.com/feed/another-heart-drug-fails-shocking-cardiologists#u58365Sat, 05 Sep 2026 18:40:59 +0000Novartis announced that its experimental cardiovascular drug pelacarsen failed to meet its primary endpoint in the Lp(a)HORIZON Phase III trial. The study targeted patients with established cardiovascular disease and elevated Lp(a). The failure of this late-stage trial has surprised cardiologists and represents a setback for a new approach to treating heart disease. The drug was developed in partnership with Ionis. Novartis released the topline results confirming the drug did not achieve the necessary goals for the pivotal study.Why it mattersPelacarsen was designed to lower Lp(a), a specific